Is CAR-T safe for early-stage patients?

Off Biotech, biotechnology, Business, cancer, CAR-T, colon cancer, drug development, drug prices, drug pricing, Health, Human Health, Life Sciences, Medicine, Oncology, Pharma, Pharmaceuticals, Politics, research, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with a reminder that my colleague Ed Silverman is hosting a discussion today about the long-awaited arrival of Humira biosimilars and all they portend for drug costs, insurance coverage, and pharma revenues. Sign up to tune in here.

Read the rest…

Read Original Article: Is CAR-T safe for early-stage patients? »

About The Author